Products

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results were published last Monday. The benefit extended across PD-L1-positive patients in the study, regardless of their level of PD-L1 expression.  Keytruda is the first...

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR) mutations. Tagrisso is already approved in the US as a second-line treatment for this subgroup of lung cancer patients, whose disease...

Farmamondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical device class II. The product was licensed to FarmaMondo on an exclusive basis for certain markets and has been approved as a novel therapy with...

FarmaMondo S.A. exclusively supplies BiCNU® (Carmustine for Injection) on an early access basis to Swiss healthcare providers. The worldwide rights for BiCNU® were acquired by Emcure Pharmaceuticals in January 2013 from Bristol-Myers Squibb. The product is available for Switzerland exclusively via FarmaMondo S.A., on a named-patient basis. As per SPC of the...

FarmaMondo SA and Rev-Pharma, a US bases pharmaceutical company, announce a Global Early Access program targeted to facilitate access to therapy for patient group suffering from an Ultra Rare dermatology disease. Curefini® dermal ointment is intended for improving the Dermatology Quality of Life (DQL) of patients with various skin disorders. It...